FDA Approves Genentech's Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

- Pivotal study showed durable responses, with a 56% overall response rate, a 43% complete response (remission) rate, and a median duration of response of 1.5 years (18.4 months) - - Given over

Related Keywords

California ,United States ,Sweden ,South San Francisco ,Canada ,Swedish ,Bruno Eschli ,Loren Kalm ,Lindsey Mathias ,Levi Garraway ,Krish Patel ,Cem Mangir ,Swedish Cancer Institute In Seattle ,Lymphoma Program ,Drug Administration ,Genentech Access Solutions ,Genentech ,Global Product Development ,Roche Group ,Global Product ,Swedish Cancer Institute ,Columvi Phase ,New England Journal ,European Medicines Agency ,Medicinal Products ,Human Use ,Genentech Access ,Largeb Cell Lymphoma Arising ,Cytokine Release Syndrome ,Columvi Patient Wallet Card ,Important Safety Information ,Serious Side Effects ,Prescribing Information ,Medication Guide ,Epstein Barr Virus ,Blood Cell Counts ,Important Safety ,Approves ,Columvi ,First ,Only ,Bispecific ,Ntibody ,Ith ,Ixed ,Uration ,Treatment ,People ,Relapsed ,Refractory ,Diffuse ,Barge ,Fell ,Lymphoma ,